tetano
Editor, Senior Moderator
Sci Rep
. 2021 May 21;11(1):10681.
doi: 10.1038/s41598-021-90111-y.
A clinical staging proposal of the disease course over time in non-severe patients with coronavirus disease 2019
Yiting Lin[SUP] 1 [/SUP], Yiqun Wu[SUP] 2 [/SUP], Ping Zhong[SUP] 3 [/SUP], Bingbo Hou[SUP] 4 [/SUP], Jielan Liu[SUP] 5 [/SUP], Yingying Chen[SUP] 6 [/SUP], Jiajun Liu[SUP] 7 [/SUP]
Affiliations
Abstract
Information on the clinical staging of coronavirus disease 2019 (COVID-19) is still limited. This study aimed to propose a clinical staging proposal of the disease course in non-severe patients with COVID-19. In this retrospective study, 108 non-severe patients with COVID-19 were grouped according to the duration from symptoms onset to hospital admission: ? 1 week, > 1 to 2 weeks, > 2 to 3 weeks, > 3 to 5 weeks, respectively. The dynamic changes of clinical signs were profiled across the four groups. A clinical staging proposal of the disease course over time was proposed from the perspective of the interaction between the virus and host. The prodromal phase, characterized by pneumonia, significant lymphopenia, and slightly elevated inflammatory markers, occurred in the first week after symptoms onset. In the second week, all the hematological and inflammatory markers were at the peak or bottom. Meanwhile, progressive pneumonia as well as the secondary damage of other organs (e.g. cardiac damage, coagulopathy, etc.) was significant during this period, making the disease progress into the apparent manifestation phase. In the third week, the improvement of the majority of clinical signs accompanied by a relatively high degree of inflammatory response defined the remission phase. After 3 weeks, patients were in the convalescent phase, in which all the indicators were maintained at a relatively normal level. We concluded that the disease course over time in non-severe patients with COVID-19 could be divided into four phases: the prodromal phase (in the first week), the apparent manifestation phase (in the second week), the remission phase (in the third week), and the convalescent phase (after 3 weeks), respectively. In clinical practice, tailored therapies should be considered seriously in different stages of the disease course.
. 2021 May 21;11(1):10681.
doi: 10.1038/s41598-021-90111-y.
A clinical staging proposal of the disease course over time in non-severe patients with coronavirus disease 2019
Yiting Lin[SUP] 1 [/SUP], Yiqun Wu[SUP] 2 [/SUP], Ping Zhong[SUP] 3 [/SUP], Bingbo Hou[SUP] 4 [/SUP], Jielan Liu[SUP] 5 [/SUP], Yingying Chen[SUP] 6 [/SUP], Jiajun Liu[SUP] 7 [/SUP]
Affiliations
- PMID: 34021206
- DOI: 10.1038/s41598-021-90111-y
Abstract
Information on the clinical staging of coronavirus disease 2019 (COVID-19) is still limited. This study aimed to propose a clinical staging proposal of the disease course in non-severe patients with COVID-19. In this retrospective study, 108 non-severe patients with COVID-19 were grouped according to the duration from symptoms onset to hospital admission: ? 1 week, > 1 to 2 weeks, > 2 to 3 weeks, > 3 to 5 weeks, respectively. The dynamic changes of clinical signs were profiled across the four groups. A clinical staging proposal of the disease course over time was proposed from the perspective of the interaction between the virus and host. The prodromal phase, characterized by pneumonia, significant lymphopenia, and slightly elevated inflammatory markers, occurred in the first week after symptoms onset. In the second week, all the hematological and inflammatory markers were at the peak or bottom. Meanwhile, progressive pneumonia as well as the secondary damage of other organs (e.g. cardiac damage, coagulopathy, etc.) was significant during this period, making the disease progress into the apparent manifestation phase. In the third week, the improvement of the majority of clinical signs accompanied by a relatively high degree of inflammatory response defined the remission phase. After 3 weeks, patients were in the convalescent phase, in which all the indicators were maintained at a relatively normal level. We concluded that the disease course over time in non-severe patients with COVID-19 could be divided into four phases: the prodromal phase (in the first week), the apparent manifestation phase (in the second week), the remission phase (in the third week), and the convalescent phase (after 3 weeks), respectively. In clinical practice, tailored therapies should be considered seriously in different stages of the disease course.